|
|
Post by mango on Oct 16, 2020 22:13:17 GMT -5
I can't speak for anyone else but I have given up on making money from afrezza. Our best hope is for a separate company to license technosphere or a dreamboat for their drug. Having said that, we are probably in a better position than we have been in a long time. John Cast Stains? |
|
|
|
Post by uvula on Oct 16, 2020 23:15:11 GMT -5
I can't speak for anyone else but I have given up on making money from afrezza. Our best hope is for a separate company to license technosphere or a dreamboat for their drug. Having said that, we are probably in a better position than we have been in a long time. John Cast Stains? Even google doesn't know what that means. |
|
|
|
Post by nylefty on Oct 16, 2020 23:53:55 GMT -5
Even google doesn't know what that means. The reference was to our old friend John Kastanes. Here's one of his recent posts on StockTwits:
|
|
|
|
Post by longliner on Oct 17, 2020 0:00:20 GMT -5
Even google doesn't know what that means. Most everyone here does. |
|
|
|
Post by mango on Oct 26, 2020 18:11:27 GMT -5
New International MannKind Patent Published 10/15/2020 A DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERYClaims 7. The inhaler of claim 6, wherein the active ingredient is a hormone, an anticoagulant, an immunomodulating agent, a vaccine, a small molecule, a cytotoxic agent, an antibiotic, a vasoactive agent, a neuroactive agent, an anaesthetic, sedative, a steroid, a decongestant, an antiviral, an antisense, an antigen, or an antibody. 8. The inhaler of claim 6, wherein the active ingredient is insulin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, follicle stimulating hormone, vasoactive intestinal peptide, parathyroid hormone, parathyroid hormone related protein, glucagon-like peptide-1, exendin, oxyntomodulin, a small molecule, peptide YY, interleukin 2-inducible tyrosine kinase, Bruton's tyrosine kinase, inositol-requiring kinase 1, PC-DAC-modified derivative, or 0-glycosylated forms of PC-DAC, parathyroid hormone 1-34, argatroban, or a combination thereof. 9. The inhaler of claim 6, wherein the active ingredient is insulin. 10. The inhaler of claim 6, wherein the active ingredient is oxyntomodulin. 11. The inhaler of claim 6, wherein the active ingredient is glucagon-like peptide-1. patentscope.wipo.int/search/en/detail.jsf?docId=AU308183219&tab=NATIONALBIBLIO&_cid=P11-KGR5EA-90756-1 |
|
|
|
Post by mango on Dec 13, 2020 22:49:04 GMT -5
|
|
|
|
Post by uvula on Dec 14, 2020 9:34:55 GMT -5
This sounds really old. "Though not yet commercially available, an ultrarapid acting insulin, insulin-fumaryl diketopiperazine (FDKP) has been under development." |
|
|
|
Post by mango on Dec 14, 2020 12:00:45 GMT -5
This sounds really old. "Though not yet commercially available, an ultrarapid acting insulin, insulin-fumaryl diketopiperazine (FDKP) has been under development." This application is a divisional of U.S. patent application Ser. No. 14/102,383, filed on Dec. 10, 2013, which is a continuation of U.S. patent application Ser. No. 13/351,855, filed on Jan. 17, 2012, which is a divisional of U.S. patent application Ser. No. 12/539,459, filed on Aug. 11, 2009, which claims benefit of priority under 35 U.S.C. § 119(e) from U.S. Provisional Patent Application Ser. Nos. 61/087,943 filed Aug. 11, 2008, 61/097,495 filed Sep. 16, 2008, 61/097,516 filed Sep. 16, 2008, and 61/138,863 filed Dec. 18, 2008, the contents of each of these applications are incorporated herein by reference in their entirety. |
|
|
|
Post by mango on Dec 17, 2020 8:45:50 GMT -5
|
|
|
|
Post by mango on Dec 17, 2020 9:04:55 GMT -5
Exogenous granulocyte macrophage colony stimulating factor can be used for a variety of medical conditions associated with COVID-19, such as pneumonia and ARDS. It also can be deployed for rare lung diseases, such as pulmonary alveolar proteinosis.
It is also part of the treatment regimen for neuroblastoma in children—Granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA) are part of the treatment regimen with Unituxin.
Unituxin of course is United Therapeutics product.
|
|
|
|
Post by lazyb767 on Jan 11, 2021 22:39:47 GMT -5
www.freepatentsonline.com/y2020/0405731.htmlAbstract: A method for treating migraines is disclosed. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent, including small molecules and peptides being administered to a patient in need of treatment. In particular, the drug delivery system is designed for inhalation for delivery of drugs to the pulmonary circulation in a rapid and therapeutically effective manner.
|
|
|
|
Post by mango on May 18, 2021 11:56:50 GMT -5
|
|
|
|
Post by mango on May 24, 2021 10:43:58 GMT -5
|
|
|
|
Post by mango on Jun 1, 2021 15:59:53 GMT -5
|
|
|
|
Post by peppy on Jun 1, 2021 16:32:25 GMT -5
Number 1 seems handy dandy. Good timing. The present invention to provide improved methods for coating crystalline particles such as fumaryl diketopiperazine (FDKP) microparticles with active agents, such as proteins, using electrostatically, hydrophobically, or hydrogen-bond driven associations. In the present invention, liquid can optionally be removed (for recovery of active agent coated microparticles) by filtration or drying, or replaced by exchanging for a different solution medium. In any case, removal of the liquid medium is not an obligatory step in formation of the active agent-microparticle complex. This invention discloses a method for microparticle coating based on changing the surface properties of the crystalline microparticles to achieve adsorption of active agent to the microparticle.In particular embodiments of the present invention, there is provided a method of coating a preformed crystalline microparticle in suspension with an active agent comprising; i) adjusting the energetic interaction between the active agent and the crystalline microparticle independent of solvent removal; and ii) allowing time for the active agent to adsorb onto the surface of the microparticle. In some embodiments, the method of coating a preformed crystalline microparticle in suspension with an active agent can further comprise a step of removing or exchanging the solvent without substantial effect on the interaction between active agent and microparticle. In other particular embodiments of the present invention, the method of coating the microparticle with active agent is accomplished by modifying the surface properties of the microparticle. Modification of the surface properties of the microparticle is achieved by altering solution conditions. These conditions, in a non-limiting manner, comprise changing the pH. In other embodiments of the invention, the surface properties of the microparticle are modified by: 1) altering the polarity of the solution; 2) the addition of monovalent or multivalent ions; and 3) chemical derivatization of the microparticle. In yet another embodiment, the present invention further comprises a step of dissolving the active agent in the fluid phase of the suspension of microparticles and subsequently changing the pH. |
|
